pharma Β· Anal Neoplasm Β· Lassa Fever Β· INO
INOVIO Pharmaceuticals
INOVIO PHARMACEUTICALS, INC.
INOVIO Pharmaceuticals patent portfolio β 75 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- 660 West Germantown Pike, Suite 110, Plymouth Meeting, PA 19462, US
- Employees
- 203
- Programs
- 46
- Drugs
- 8
- Patents
- 75
INOVIO Pharmaceuticals patents
75 pharmaceutical patents indexed for INOVIO Pharmaceuticals. 0 expire within 24 months.
INOVIO Pharmaceuticals has 75 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months β use filters for patent-cliff planning.
Patent portfolio
-
US 12285473
Cancer vaccines targeting MUC16 and uses thereof
granted -
US 12280108
Vaccines having an antigen and interleukin-21 as an adjuvant
granted -
US 12251561
Minimally invasive dermal electroporation device
granted -
US 12240872
Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
granted -
US 12161706
Cancer vaccines targeting BORIS and uses thereof
granted -
US 12109258
Synthetic malaria immunogens, combinations thereof, and their use to prevent and treat malaria infections
granted -
US 12064473
Cancer vaccines targeting Survivin and uses thereof
granted -
US 12054537
Optimized nucleic acid antibody constructs encoding anti-respiratory syncytial virus (RSV) antibodies
granted -
US 12053619
Intradermal jet injection electroporation
granted -
US 12049479
Foot and mouth disease virus (FMDV) consensus proteins, coding sequences therefor and vaccines made therefrom
granted -
US 11986517
Cancer vaccines targeting mesothelin and uses thereof
granted -
US 11980659
Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same
granted -
US 11981724
DNA antibody constructs for use against middle east respiratory syndrome coronavirus
granted -
US 11925685
DNA antibody constructs encoding anti-ZIKV envelope antibodies
granted -
US 11896654
DNA monoclonal antibodies targeting checkpoint molecules
granted -
US 11865166
Nucleic acid encoding optimized immunogenic peptide that targets follicle stimulating hormone receptor
granted -
US 11851477
DNA monoclonal antibodies targeting influenza virus
granted -
US 11844830
Vaccines for human papilloma virus and methods for using the same
granted -
US 11845787
DNA antibody constructs for use against HIV
granted -
US 11801288
Cancer vaccines and methods of treatment using the same
granted -
US 11801298
MERS-CoV vaccine
granted -
US 11744885
Vaccines for recurrent respiratory papillomatosis and methods of using the same
granted -
US 11660335
Vaccines against coronavirus and methods of use
granted -
US 11638747
WT1 vaccine
granted -
US 11565107
Tolerable and minimally invasive skin electroporation device
granted -
US 11464841
TERT immunogenic compositions and methods of treatment using the same
granted -
US 11338029
Cancer vaccines targeting PRAME and uses thereof
granted -
US 11338028
Cancer vaccines targeting LEMD1 and uses thereof
granted -
US 11291836
Minimally invasive dermal electroporation device
granted -
US 11278619
DNA antibody constructs and method of using same
granted -
US 11235044
Cancer vaccines targeting MUC16 and uses thereof
granted -
US 11230592
DNA antibody constructs for use against middle east respiratory syndrome coronavirus
granted -
US 11208470
DNA antibody constructs and method of using same
granted -
US 11154602
Cancer vaccines targeting mesothelin and uses thereof
granted -
US 11154601
Cancer vaccines targeting BORIS and uses thereof
granted -
US 11135284
MERS-CoV vaccine
granted -
US 11124545
Foot and mouth disease virus (FMDV) consensus proteins, coding sequences therefor and vaccines made therefrom
granted -
US 11116838
Checkpoint inhibitor and vaccine combinations and use of same for immunotherapy
granted -
US 11091518
Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
granted -
US 11045535
Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same
granted -
US 11027071
Intradermal jet injection electroporation device
granted -
US 11007255
Cancer vaccines and methods of treatment using the same
granted -
US 11007265
Vaccines having an antigen and interleukin-21 as an adjuvant
granted -
US 10933130
Vaccines with interleukin-33 as an adjuvant
granted -
US 10925961
Vaccines with CD40 ligand as an adjuvant
granted -
US 10905755
Vaccines for human papilloma virus and methods for using the same
granted -
US 10835595
PD1 and PDL1 antibodies and vaccine combinations and use of same for immunotherapy
granted -
US 10668279
Miniminally invasive dermal electroporation device
granted
Frequently asked questions
How many patents does INOVIO Pharmaceuticals have?
75 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do INOVIO Pharmaceuticals patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.